NEW YORK (GenomeWeb News) – Advanced Biological Laboratories has reached cross-license and strategic alliance agreements with Luxembourg-based Evivar, Melbourne, Australia-based ABL said today.
The companies have agreed to develop and commercialize their products, including ABL's TherapyEdge and Evivar's SeqHepB system, for use in management and treatment of HIV and Hepatitis B.
The SeqHepB system is a viral genomics sequence analysis program that is linked to a centralized HBV genomic database. It can be used to identify HBV mutations present in patients and predict their resistance levels to various available medications.
The TherapyEdge is a patient record hospital information system that is used for data and patient management, monitoring, and reporting applications. It also is used for personalized therapy selection, the firms said.
"The combined platforms offer virologists and physicians diagnosing and treating hepatitis and HIV with enhanced clinical and research management tools," Evivar CEO Bernie Romanin said in a statement.